AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32708973
Drug: Iron-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-rich diet (iron intake >20 mg/day)
Trial: 32708973
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (FS) supplementation (105 mg/day)
Trial: 34518652
Drug: Enzalutamide plus
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide plus androgen deprivation therapy (ADT)
Trial: 33433597
Drug: Salt nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt nicotine formulation (benzoic acid added)
Trial: 32357362
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol maleate (TTM) 0.5% solution for 12 months
Trial: 32357362
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol maleate (TTM) 0.5% solution
Trial: 32267471
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg, subcutaneously at weeks 0 and 4
Trial: 36162893
Drug: 1-visit root
RxNorm normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-visit root canal treatment with 2% chlorhexidine (CHX) as final irrigant
Trial: 36162893
Drug: 2-visit root
RxNorm normalized name: Mugwort root
DrugBank: Artemisia vulgaris root (DB14170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-visit root canal treatment with calcium hydroxide (CH) dressings
Trial: 33028480
Drug: MAP +
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAP + Treatment as Usual (TAU)
Trial: 33907936
Drug: One-implant group
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-implant group (n = 23)
Trial: 33907936
Drug: Two-implant group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant group (n = 24)
Trial: 32211907
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg (0.05 mL)
Trial: 32796329
Drug: Buried Intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buried Intradermal Suture (BIS)
Trial: 35488808
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy Group (ATG)
Trial: 35488808
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy Group (ATG) with initial severe mental fatigue (MFF)
Trial: 35488808
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy Group (ATG) with initial poor motivation
Trial: 35488808
Drug: Art Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art Therapy Group (ATG) with chemotherapy
Trial: 35488808
Drug: Standard Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Group (SG) with chemotherapy
Trial: 37592290
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy
Trial: 36442482
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic target <40th percentile)
Trial: 33834643
Drug: Desmopressin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin plus anticholinergic (propiverine 5 mg)
Trial: 33834643
Drug: Desmopressin (monotherapy)
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (monotherapy)
Trial: 35870327
Drug: Parent-based treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-based treatment
Trial: 34301613
Drug: brolucizumab 6
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brolucizumab 6 mg
Trial: 33187542
Drug: Smartphone-assisted problem-solving
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-assisted problem-solving therapy
Trial: 33059084
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation treatment (Control)
Trial: 34472929
Drug: Mindfulness Meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Meditation (MM), Cognitive Therapy (CT), Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 34237764
Drug: Usual discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual discharge pain medication instructions
Trial: 35012708
Drug: ESS plus
RxNorm normalized name: Stress Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESS plus medical therapy
Trial: 35065931
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of PM2.5 exposure (≥ 129.9 and ≤ 2100 μg/m3)
Trial: 33211109
Drug: Long-term current
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term current low-dose aspirin use
Trial: 33211109
Drug: Episodic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Episodic low-dose aspirin use
Trial: 33211109
Drug: Long-term current
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term current low-dose aspirin use (subcohort aged 40-59 years)
Trial: 33211109
Drug: Episodic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Episodic low-dose aspirin use (subcohort aged 40-59 years)
Trial: 33211109
Drug: No low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No low-dose aspirin use (control group)
Trial: 34656303
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) and elemental zinc (30 mg) daily for 6 months
Trial: 32467559
Drug: Immediate-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tacrolimus (0.2 mg/kg/day)
Trial: 32467559
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus (0.2 mg/kg/day)
Trial: 32467559
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus (0.3 mg/kg/day)
Trial: 32467559
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab
Trial: 35675611
Drug: Same-day cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day cervical preparation with osmotic dilators plus buccal misoprostol
Trial: 33431358
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with combination cisplatin (50 mg/m2) plus doxorubicin (15 mg/m2)
Trial: 33431358
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with intense single-agent cisplatin (100 mg/m2)
Trial: 35862782
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg intragastric administration)
Trial: 35862782
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no simvastatin treatment)
Trial: 33674231
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy (Med)
Trial: 33031018
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BR) - 70 mL (∼5 mmol nitrate)
Trial: 33031018
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) - 70 mL (∼0.003 mmol nitrate)
Trial: 35500015
Drug: READY (Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: READY (Acceptance and Commitment Therapy-based group resilience-training program)
Trial: 35307538
Drug: Family-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused therapy with medication management as needed
Trial: 35307538
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care psychoeducation with medication management as needed
Trial: 35307538
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Family-focused therapy and Enhanced care psychoeducation)
Trial: 34129239
Drug: Antithrombotic therapies
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapies (ATT)
Trial: 34129239
Drug: Monotherapy (Low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Low-dose aspirin)
Trial: 34129239
Drug: DAPT (Aspirin/Clopidogrel)
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (Aspirin/Clopidogrel)
Trial: 35448942
Drug: IV HBB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV HBB 20 mg in 1 ml (Hyoscine group)
Trial: 32685258
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid (10 mg/kg)
Trial: 33827781
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy in earlier trials
Trial: 35422208
Drug: Regional Anesthesia
RxNorm normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional Anesthesia (RA) with Dexmedetomidine (DEX: 1 μg/kg infused over 10 min followed by 0.5 μg/kg/h)
Trial: 35422208
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia (GA) with Dexmedetomidine (DEX: 0.1 μg/kg/min over 10 min followed by 0.4‐0.7 μg/kg/h)
Trial: 32594135
Drug: prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone (10 mg daily) plus 5α-reductase inhibitor (finasteride 5 mg daily or dutasteride 0.5 mg daily)
Trial: 32594135
Drug: prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone (10 mg daily)
Trial: 36120087
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 3350 17g once daily for 24 weeks
Trial: 35177180
Drug: Budesonide combined
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide combined with pulmonary surfactant (PS) at a dose of 0.25 mg/kg for intratracheal instillation with PS application.
Trial: 35177180
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with pulmonary surfactant (PS) alone at an initial dose of 200 mg/kg, followed by 100 mg/kg according to the condition.
Trial: 32151211
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of intravenous zoledronate
Trial: 35608106
Drug: Oral infigratinib
RxNorm normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral infigratinib 125 mg daily on days 1-21 of a 28-day cycle for up to 52 weeks
Trial: 37332625
Drug: Standard literacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard literacy promotion (beginning at 6 months, only weekly text messages on safety)
Trial: 33398890
Drug: Mefloquine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (2 doses taken as a split dose with a meal)
Trial: 33398890
Drug: Sulfadoxine–pyrimethamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine–pyrimethamine (4 doses)
Trial: 35329896
Drug: Exergame intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exergame intervention (20 minutes, twice per week)
Trial: 32499254
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus KOMPACT (2 hours 20 minutes of preoperative physiotherapy informed by Acceptance and Commitment Therapy)
Trial: 33070288
Drug: Alpelisib 300
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 300 mg in fasted state
Trial: 33070288
Drug: Pivotal clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivotal clinical formulation (PCF) and commercial formulation (CF)
Trial: 32857331
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days antibiotics
Trial: 32857331
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days antibiotics
Trial: 34151493
Drug: Oral cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporine (3 mg/kg/day) for 4 months
Trial: 34151493
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone mini pulse (2.5 mg dexamethasone on two consecutive days/week for 4 months)
Trial: 32700655
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg oral daily (group RXE)
Trial: 34302514
Drug: 8% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% capsaicin treatment
Trial: 32772049
Drug: Personalized medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized medicine based on human genetics for cardiovascular diseases
Trial: 34724045
Drug: Crystalloid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalloid administration
Trial: 35521789
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg s.c. injection)
Trial: 35521789
Drug: Copeptin cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin cut-off level of 4.6 pmol/L
Trial: 39555827
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment targeting systolic blood pressure <120 mm Hg
Trial: 39555827
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment targeting systolic blood pressure <140 mm Hg
Trial: 36308110
Drug: Intracameral lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracameral lidocaine hydrochloride 1% and tropicamide injection 0.02%
Trial: 34714539
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (0.3 mL/kg of 0.25 percent bupivacaine, fentanyl 50 µg, and naloxone 100 ng)
Trial: 34714539
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (0.3 mL/kg of 0.25 percent bupivacaine)
Trial: 34714539
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (0.3 mL/kg of 0.25 percent bupivacaine and fentanyl 50 µg)
Trial: 36175722
Drug: Biologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapy prior to surgery
Trial: 36175722
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no biologic therapy)
Trial: 34137476
Drug: Dipyridamole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (up to 300 mg)
Trial: 36244879
Drug: Standard-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose influenza vaccine (SD)
Trial: 33769732
Drug: Methotrexate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (0.3 mg/kg/week)
Trial: 33769732
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Methotrexate (0.15 mg/kg/week) and Cyclosporine (2.5 mg/kg/day)
Trial: 37449426
Drug: Automated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Insulin Delivery (AID)
Trial: 34756489
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping (KT) on extensor carpi radialis brevis and longus (ECRB/L)
Trial: 34756489
Drug: Placebo taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taping (PT) on extensor carpi radialis brevis and longus (ECRB/L)
Trial: 35807160
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% fluorometholone combined with 0.05% azelastine
Trial: 35807160
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% fluorometholone alone
Trial: 35807160
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (combination and isolated fluorometholone)
Trial: 33774558
Drug: Internet-delivered exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered exposure therapy
Trial: 33774558
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (iCBT)
Trial: 35218019
Drug: Targeted temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted temperature treatment (TTM) at 33°C for 24 or 48 hours
Trial: 34988932
Drug: NeuroMuscular Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroMuscular Taping (NMT) applied over 8 days following back-school therapy (BST)
Trial: 34988932
Drug: Back-school therapy
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back-school therapy (BST) alone
Trial: 34507361
Drug: Gonyautoxin 2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonyautoxin 2/3 (GTX 2/3) 40 ?g in 30 mL sodium chloride 0.9%
Trial: 34507361
Drug: Levobupivacaine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (300 mg), ketorolac (60 mg), and epinephrine (1 mg) in 150 mL sodium chloride 0.9%
Trial: 35968286
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Mecobalamin tablets)
Trial: 34496751
Drug: Education based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education based on Acceptance and Commitment Therapy (ACT)
Trial: 35233984
Drug: Goserelin (Z),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (Z), 3.6 mg, n = 8
Trial: 33176437
Drug: Omecamtiv Mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv Mecarbil (OM) 25 mg BID
Trial: 33176437
Drug: Omecamtiv Mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv Mecarbil (OM) pharmacokinetically guided dose titration (OM-PK)
Trial: 34606293
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene system (test group) involving a novel smart‐connected Oral‐B® iO oscillating‐rotating electric toothbrush, 0.454 percent stabilized stannous fluoride dentifrice, 0.07 percent cetylpyridinium chloride rinse, and floss
Trial: 32806525
Drug: Face-to-face exercise
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face exercise performed by an instructor (Group L)
Trial: 34282647
Drug: 3-minute dilute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-minute dilute povidone-iodine soak and scrub followed by standard 2-step skin preparation (alcohol scrub and chlorhexidine/alcohol paint)
Trial: 34282647
Drug: Standard 2-step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2-step skin antiseptic preparation (alcohol scrub followed by chlorhexidine/alcohol paint)
Trial: 32985369
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 15 mg/kg TXA